Amphiregulin triggered epidermal growth factor receptor activation confers <i>in vivo</i> crizotinib‐resistance of <scp>EML</scp>4‐<scp>ALK</scp> lung cancer and circumvention by epidermal growth factor receptor inhibitors
Hirokazu Taniguchi(Memorial Sloan Kettering Cancer Center), Seiji Yano(Kanazawa University Hospital)
Cited by 33
Related Papers
Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study
|Cancer Science|2019|375
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
|Nature Communications|2019|360
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
|Human Molecular Genetics|2004|174
Targeted Therapies and Biomarkers in Small Cell Lung Cancer
|Frontiers in Oncology|2020|112
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
|Nature Communications|2020|112